@article{3178900,
    title = "Atezolizumab (atezo) vs. chemotherapy (chemo) in platinum-treated
locally advanced or metastatic urothelial carcinoma (mUC): Immune
biomarkers, tumor mutational burden (TMB), and clinical outcomes from
the phase III IMvigor211 study.",
    author = "Powles, Thomas and Loriot, Yohann and Ravaud, Alain and Vogelzang, and Nicholas J. and Duran, Ignacio and Retz, Margitta and De Giorgi, Ugo and and Oudard, Stephane and Bamias, Aristotelis and Koeppen, Hartmut and Leng, and Ning and Kadel, Edward E. and Hegde, Priti S. and Cui, Na and Shen, and Xiaodong and Derleth, Christina Louise and Green, Marjorie C. and and Banchereau, Romain and Mariathasan, Sanjeev and Van Der Heijden, Michiel and Simon",
    journal = "World Journal of Clinical Oncology",
    year = "2018",
    volume = "36",
    number = "6, S",
    publisher = "Lippincott, Williams & Wilkins",
    doi = "10.1200/JCO.2018.36.6_suppl.409"
}